Nevertheless, despite the remarkable efficacy of CTLA-4 and PD1-PDL1(programmed cell death 1 ligand 1)-targeted therapies in cancer immunotherapy, a significant proportion of patients exhibit a restricted response to these treatments. The gene discussed is CTLA4; the disease is cancer.